Target-mediated drug disposition model: Relationships with indirect response models and application to population PK-PD analysis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 4, 2009, Pages 341-351

  Gibiansky, Leonid ^a   Gibiansky, Ekaterina ^b  

^a QuantPharm LLC 49 Flints Grove Drive   (United States)

^b ICON Development Solutions   (United States)

Author keywords

Indirect response models; Michaelis Menten approximation; Nonlinear pharmacokinetics; Pharmacodynamics; Quasi steady state approximation; Target mediated drug disposition

Indexed keywords

MONOCLONAL ANTIBODY; OMALIZUMAB;

ARTICLE; COMPUTER PROGRAM; COMPUTER SIMULATION; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG TARGETING; HUMAN; INTERNALIZATION; MATHEMATICAL MODEL; MICHAELIS MENTEN KINETICS; NONLINEAR SYSTEM; PHARMACODYNAMICS; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEADY STATE; TARGET MEDIATED DRUG DISPOSITION;

ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOKINETICS; SOFTWARE;

EID: 69049088695     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9125-9     Document Type: Article

References (13)

1. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 507 532
2. DE Mager W Krzyzanski 2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition Pharm Res 22 10 1589 1596
3. L Gibiansky E Gibiansky T Kakkar P Ma 2008 Approximations of the target-mediated drug disposition model and identifiability of model parameters J Pharmacokinet Pharmacodyn 35 5 573 591
4. L Gibiansky E Gibiansky 2009 Target-mediated drug disposition model: approximations, identifiability of model parameters, and applications to the population pharmacokinetic - pharmacodynamic modeling of biologics Expert Opinion Drug Metab Toxicol 5 7 803 812
5. NL Dayneka V Garg WJ Jusko 1993 Comparison of four basic models of indirect pharmacodynamic responses J Pharmacokinet Biopharm 21 457 478
6. RJ Bauer DL Russel RL White MJ Murray MR Garovoy 1999 Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis J Pharmacokinet Biopharm 27 4 397 420
7. Kuester K, Kloft C (2006) Pharmacokinetics of monoclonal antibodies. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. WILEY-VCH Verlag GmbH & Co, KGaA, Weinheim, pp 45-91
8. DR Mould KD Sweeney 2007 A review of the pharmacokinetics and pharmacodynamics of monoclonal antibodies - mechanistic modeling applied to drug development Current Opinion Drug Discov Devel 10 1 84 96
9. W Wand EQ Wang JP Balthasar 2008 Monoclonal antibody pharmacokinetics and pharmacodynamics Clin Pharmacol Ther 84 5 548 558
10. Beal SL, Sheiner LB, Boeckmann AJ (eds) (1989-2007) NONMEM users guides. Icon Development Solutions, Ellicott City, MD, USA
11. Nonmem VI®. NONMEM Project Group. University of California at San Francisco: San Francisco, CA, USA
12. GML Meno-Tetang PJ Lowe 2005 On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach Basic Clin Pharmacol Toxicol 96 3 182 192
13. N Hayashi Y Tsukamoto WM Sallas PJ Lowe 2007 A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab Br J Clin Pharmacol 63 5 548 561